AdipoPharma
AdipoPharma is a French biotechnology company developing PATAS, a first-in-class therapeutic stapled peptide designed to treat insulin resistance and type 2 diabetes. The drug acts directly on adipocytes to restore natural metabolic function, reduce toxic lipids like ceramides, and address associated comorbidities such as liver steatosis and fibrosis. The company targets the root causes of metabolic dysfunction rather than symptom management, with clinical trials scheduled to begin in 2025.
Visit websiteStrasbourg, France
Biotechnology
Healthtech
Pharmaceuticals
Funding summary
- Total raised
- €0
- Funding rounds
- 1
Investors in AdipoPharma
Investors on record for AdipoPharma. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like AdipoPharma?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors